MX2020012478A - Metodos y composiciones para el tratamiento de la hipertension pulmonar. - Google Patents
Metodos y composiciones para el tratamiento de la hipertension pulmonar.Info
- Publication number
- MX2020012478A MX2020012478A MX2020012478A MX2020012478A MX2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A MX 2020012478 A MX2020012478 A MX 2020012478A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- pulmonary hypertension
- treating pulmonary
- rapamycin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675110P | 2018-05-22 | 2018-05-22 | |
| US201962810290P | 2019-02-25 | 2019-02-25 | |
| US201962820838P | 2019-03-19 | 2019-03-19 | |
| US201962820842P | 2019-03-19 | 2019-03-19 | |
| PCT/US2019/033372 WO2019226685A1 (en) | 2018-05-22 | 2019-05-21 | Methods and compositions for treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012478A true MX2020012478A (es) | 2021-03-09 |
Family
ID=68615837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012478A MX2020012478A (es) | 2018-05-22 | 2019-05-21 | Metodos y composiciones para el tratamiento de la hipertension pulmonar. |
| MX2024010373A MX2024010373A (es) | 2018-05-22 | 2020-11-20 | Metodos y composiciones para el tratamiento de la hipertension pulmonar. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010373A MX2024010373A (es) | 2018-05-22 | 2020-11-20 | Metodos y composiciones para el tratamiento de la hipertension pulmonar. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210085621A1 (https=) |
| EP (1) | EP3810091A4 (https=) |
| JP (1) | JP7561628B2 (https=) |
| KR (1) | KR20210024471A (https=) |
| CN (1) | CN112423737A (https=) |
| AU (1) | AU2019274516B2 (https=) |
| BR (1) | BR112020023431A2 (https=) |
| CA (1) | CA3100905A1 (https=) |
| IL (1) | IL278814A (https=) |
| MX (2) | MX2020012478A (https=) |
| NZ (1) | NZ770290A (https=) |
| SG (1) | SG11202011462SA (https=) |
| TW (1) | TW202015659A (https=) |
| WO (1) | WO2019226685A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| MX2021011230A (es) * | 2019-03-19 | 2022-03-11 | Abraxis Bioscience Llc | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| KR20220120823A (ko) | 2021-02-24 | 2022-08-31 | 주식회사 만도 | 랙구동형 동력 보조 조향장치 |
| CN114732789B (zh) * | 2022-05-05 | 2023-08-22 | 中国药科大学 | 一种用于治疗肺动脉高压的复方长效递药系统及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| CN105879114A (zh) | 2005-02-18 | 2016-08-24 | 阿布拉西斯生物科学公司 | 用于整合入医疗装置的疏水性改善的药物 |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| KR20170095807A (ko) * | 2014-10-07 | 2017-08-23 | 램 테라퓨틱스, 인코포레이티드 | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 |
| US20180256551A1 (en) * | 2015-06-29 | 2018-09-13 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| HK1247093A1 (zh) * | 2015-06-29 | 2018-09-21 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| US20180177771A1 (en) * | 2015-06-29 | 2018-06-28 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| PL3998069T3 (pl) * | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| EP3518923A4 (en) * | 2016-09-28 | 2020-06-17 | Abraxis BioScience, LLC | METHOD FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS |
-
2019
- 2019-05-21 CN CN201980048031.5A patent/CN112423737A/zh active Pending
- 2019-05-21 TW TW108117571A patent/TW202015659A/zh unknown
- 2019-05-21 EP EP19807397.5A patent/EP3810091A4/en active Pending
- 2019-05-21 KR KR1020207036401A patent/KR20210024471A/ko not_active Ceased
- 2019-05-21 AU AU2019274516A patent/AU2019274516B2/en not_active Expired - Fee Related
- 2019-05-21 CA CA3100905A patent/CA3100905A1/en active Pending
- 2019-05-21 NZ NZ770290A patent/NZ770290A/en unknown
- 2019-05-21 WO PCT/US2019/033372 patent/WO2019226685A1/en not_active Ceased
- 2019-05-21 BR BR112020023431-1A patent/BR112020023431A2/pt unknown
- 2019-05-21 JP JP2020565354A patent/JP7561628B2/ja active Active
- 2019-05-21 MX MX2020012478A patent/MX2020012478A/es unknown
- 2019-05-21 SG SG11202011462SA patent/SG11202011462SA/en unknown
-
2020
- 2020-11-18 IL IL278814A patent/IL278814A/en unknown
- 2020-11-19 US US16/953,167 patent/US20210085621A1/en active Pending
- 2020-11-20 MX MX2024010373A patent/MX2024010373A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ770290A (en) | 2025-06-27 |
| MX2024010373A (es) | 2024-09-02 |
| US20210085621A1 (en) | 2021-03-25 |
| IL278814A (en) | 2021-01-31 |
| AU2019274516A1 (en) | 2020-12-17 |
| CA3100905A1 (en) | 2019-11-28 |
| AU2019274516B2 (en) | 2025-04-03 |
| EP3810091A4 (en) | 2022-03-02 |
| JP7561628B2 (ja) | 2024-10-04 |
| JP2021526138A (ja) | 2021-09-30 |
| TW202015659A (zh) | 2020-05-01 |
| CN112423737A (zh) | 2021-02-26 |
| WO2019226685A1 (en) | 2019-11-28 |
| BR112020023431A2 (pt) | 2021-02-23 |
| KR20210024471A (ko) | 2021-03-05 |
| SG11202011462SA (en) | 2020-12-30 |
| EP3810091A1 (en) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010373A (es) | Metodos y composiciones para el tratamiento de la hipertension pulmonar. | |
| SA522431915B1 (ar) | Prmt5 مثبطات mta تعاونية مع | |
| PH12020551205A1 (en) | Fap inhibitors | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| EA202091114A1 (ru) | Новые высокоактивные пиразолопиперидин-замещенные индол-2-карбоксамиды, активные против вируса гепатита в (hbv) | |
| EP3326630A3 (en) | Methods and compositions for treating pulmonary hypertension | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| MX391339B (es) | Composicion farmaceutica que comprende selexipag. | |
| EA201990820A1 (ru) | Способы лечения митохондриальных и метаболических нарушений | |
| MX384206B (es) | Formulaciones de inhibidores de dpp iv | |
| EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
| EA201170520A1 (ru) | Ингибитор p38 mapk-киназы | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| SMT201300096B (it) | Inibitori di prolil idrossilasi | |
| PH12013500648A1 (en) | Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors | |
| MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| EA201000329A1 (ru) | Циклические депсипептиды | |
| FI20115234A0 (fi) | Uusia pyridatsinoni- ja pyridoniyhdisteitä | |
| NO20074536L (no) | Anvendelse av jern (III)-komplekssammensetninger |